Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Nov 21, 2011
Dr. Richard Moxley discusses how NIAMS and NIH funding has moved the field of muscular dystrophy research forward via a critical disease registry, a network of research centers, and individual study grants. He discusses the strides being made, particularly in the field of myotonic dystrophy—the most common of the muscular dystrophies—"because of the breakthroughs that we think we are now poised to pursue," including the discovery that toxic ribonucleic acid (RNA) causes the gene defect in myotonic dystrophy and the exciting advances that have been made in treating the disease in animal models.